Arrhythmias & electrophysiology
The Feasibility and Safety of Flecainide Use Among Patients With Varying Degrees of Coronary Disease
Main finding · Event-free survivalResult — go to the resultHazard ratio 3.80 95% CI 1.67–8.67Authors' conclusion
Among select patients with nonobstructive CAD and without a history of ventricular tachycardia, IC agents are not associated with increased mortality.
Study context
- Population
- Patients on antiarrhythmic agents with varying degrees of coronary artery disease (CAD) (none, nonobstructive, obstructive), without prior VT, ICD placement or nonrevascularized MI, 2005–2021
- Participants
- 3,445 vs 2,216
- Exposure
- Class IC antiarrhythmic agents vs sotalol or dofetilide
- IC agentn = 3,445
- Sotalol or dofetiliden = 2,216reference
- Outcome
- Event-free survival (incl. mortality)
Methodological detailssingle-centre
- Single-centre
Main finding
Event-free survival
Hazard ratio
3.80
95% CI 1.67–8.67
P = 0.002
IC agentvs Sotalol
HR 3.80 (95% CI 1.67–8.67); P = 0.002
As reported in the abstract
Observational data: associations, not effects.
Original publication
The Feasibility and Safety of Flecainide Use Among Patients With Varying Degrees of Coronary Disease. JACC Clin Electrophysiol. Published 22 February 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →